{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:32:20Z","timestamp":1793118740860,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ygyno.2026.10.013","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:00:30Z","timestamp":1792789230000},"page":"164-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phase II study of cabozantinib in recurrent or metastatic cervical cancer after progression on platinum-based chemotherapy (CABOCOL)"],"prefix":"10.1016","volume":"214","author":[{"given":"Elodie","family":"Coquan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Vion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Colomba-Blamemble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Abdeddaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"D'Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coraline","family":"Dubot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Brachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Castera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludivine","family":"Beaussire-Trouvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lequesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2026.10.013_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.013_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100579","article-title":"Recurrent or primary metastatic cervical cancer: current and future treatments","volume":"7","author":"Gennigens","year":"2022","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ygyno.2026.10.013_bb0015","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.013_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann. Oncol."},{"issue":"36","key":"10.1016\/j.ygyno.2026.10.013_bb0025","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line Pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical Cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.013_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.013_bb0035","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with cervical cancer - Update 2023","volume":"33","author":"Cibula","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2026.10.013_bb0040","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN guidelines\u00ae insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ygyno.2026.10.013_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115146","article-title":"Cemiplimab in recurrent cervical cancer: final analysis of overall survival in the phase III EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9 trial","volume":"216","author":"Oaknin","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.013_bb0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as second- or third-line therapy for recurrent cervical Cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2026.10.013_bb0055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.6004\/jnccn.2025.0057","article-title":"Cervical cancer, version 2.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"12","key":"10.1016\/j.ygyno.2026.10.013_bb0060","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.ygyno.2026.10.013_bb0065","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1158\/0008-5472.CAN-10-0489","article-title":"HGF\/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors","volume":"70","author":"Shojaei","year":"2010","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.ygyno.2026.10.013_bb0070","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2026.10.013_bb0075","doi-asserted-by":"crossref","first-page":"6594016","DOI":"10.1155\/2016\/6594016","article-title":"Diagnosis and prognostic significance of c-met in cervical Cancer: a Meta-analysis","volume":"2016","author":"Peng","year":"2016","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ygyno.2026.10.013_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221107112","article-title":"Cabozantinib for the treatment of solid tumors: a systematic review","volume":"14","author":"Maroto","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.013_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/14737140.2024.2337266","article-title":"Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis","volume":"24","author":"Su","year":"2024","journal-title":"Expert Rev. Anticancer. Ther."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.013_bb0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clgc.2023.11.001","article-title":"Cabozantinib in the routine Management of Renal Cell Carcinoma: a systematic literature review of real-world evidence","volume":"22","author":"Gross-Goupil","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.013_bb0095","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1186\/s12885-021-08758-9","article-title":"CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure","volume":"21","author":"Coquan","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2026.10.013_bb0100","doi-asserted-by":"crossref","first-page":"1382008","DOI":"10.3389\/fonc.2024.1382008","article-title":"Prognostic value of HPV circulating tumor DNA detection and quantification in locally advanced cervical cancer","volume":"14","author":"Beaussire-Trouvay","year":"2024","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.013_bb0105","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2307\/2533268","article-title":"Incorporating toxicity considerations into the design of two-stage phase II clinical trials","volume":"51","author":"Bryant","year":"1995","journal-title":"Biometrics"},{"issue":"7","key":"10.1016\/j.ygyno.2026.10.013_bb0110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2026.10.013_bb0115","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.10.013_bb0120","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s12094-017-1808-x","article-title":"Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in \u00ab real world \u00bb patients","volume":"20","author":"Godoy-Ortiz","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ygyno.2026.10.013_bb0125","article-title":"Hypoalbuminemia is a predictive factor for fistula formation in recurrent cervical cancer","author":"Palavalli Parsons","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.013_bb0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2009.08.012","article-title":"A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG trial IND.184","volume":"116","author":"Mackay","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2026.10.013_bb0135","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S1470-2045(15)00220-X","article-title":"Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Symonds","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.10.013_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2023.04.028","article-title":"Randomized phase II BGOG\/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer","volume":"174","author":"Vergote","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"34","key":"10.1016\/j.ygyno.2026.10.013_bb0145","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus Apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.013_bb0150","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cac2.12547","article-title":"Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study","volume":"44","author":"Lan","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"issue":"16","key":"10.1016\/j.ygyno.2026.10.013_bb0155","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.013_bb0160","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10103","key":"10.1016\/j.ygyno.2026.10.013_bb0165","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Final overall survival of the phase III randomised trial of chemotherapy with and without bevacizumab for advanced cervical Cancer: an NRG oncology\/gynecologic oncology group study","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.013_bb0170","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12885-022-09695-x","volume":"22","author":"Hwang","year":"2022","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2026.10.013_bb0175","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.013_bb0180","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.013_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100154","article-title":"HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer","volume":"6","author":"Cabel","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.ygyno.2026.10.013_bb0190","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.101887","article-title":"Monitoring circulating cell-free HPV DNA in metastatic or recurrent cervical cancer: clinical significance and treatment implications","volume":"13","author":"Yin","year":"2025","journal-title":"Elife"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:20Z","timestamp":1793115320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S0090825826021633"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.10.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of cabozantinib in recurrent or metastatic cervical cancer after progression on platinum-based chemotherapy (CABOCOL)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}